A Phase 2 interventional study of AP-101 and Placebo in Amyotrophic Lateral Sclerosis, sponsored by AL-S Pharma. Completed at 13 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by AL-S Pharma · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada — 15 open to participants now, 25 under way, 5 of them phase 3. Amyotrophic Lateral Sclerosis · Canada.
Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, this one is the 38th largest by enrollment of the 72 interventional ones that give a count, is one of 9 that started in 2021, is one of 21 in phase 2, and was the 54th registered.
980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.
Browse Amyotrophic Lateral Sclerosis studies →15 of the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Canada, Belgium, Germany and 2 more countries
Ages 18–80
Eli Lilly and Company · Sites in Canada, Belgium, Germany and 2 more countries
Ages 18–80
Nura Bio · Sites in Canada, Australia, Netherlands and 1 more country
Ages 18–80
Prilenia · Sites in Canada, United States, Belgium and 10 more countries
Ages 18–80
Zydus Therapeutics Inc. · Sites in Canada, United States, Australia and 9 more countries
Ages 18+
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 29 · Phase 3 23 · Phase 4 1
First in 2001; this study’s year is marked. 9 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 73 is above the median of 38 across 664 interventional studies indexed under Amyotrophic Lateral Sclerosis.
Median enrollment 75 across the 72 interventional studies, 148 across the 10 observational. Of the 49 that completed or were terminated, 24 (49%) have results posted.
This tab as a report to print or save as PDF → With an account.
56 of 82 have an industry lead sponsor. The 10 most frequent:
AL-S Pharma is the lead sponsor of 2 studies on the registry; none are open to participants now.
AL-S Pharma has 2 studies filed under Amyotrophic Lateral Sclerosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Amyotrophic Lateral Sclerosis with a site in Canada that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07161999Phase 3Coya TherapeuticsStudy of COYA 302 for the Treatment of ALS | 2027-04 |
| NCT04057898Phase 3MediciNovaEvaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS | 2027-04 |
| NCT04856982Phase 3BiogenStudy to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms | 2027-08-07 |
| NCT07193953Sunnybrook Health Sciences CentreIntravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | 2026-11-30 |
| NCT06051123Centre hospitalier de l'Université de Montréal (CHUM)Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients | 2027-02 |
Add all 11 to your calendar (.ics) → With an account.
Among the 82 studies in Amyotrophic Lateral Sclerosis with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.
This Phase 2a, multicenter, randomized, double-blind, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamic markers of AP-101 in adults with sporadic ALS or SOD1-associated ALS. A total of 73 participants were randomized within each ALS cohort in a 2:1 ratio to receive AP-101 or placebo during a 24-week double-blind treatment period.
Participants assigned to AP-101 received a 500 mg intravenous loading dose on Day 1, a 2500 mg intravenous dose on Day 2, and 2500 mg intravenously every 3 weeks beginning on Day 22 through Week 24. Participants assigned to placebo received matching intravenous infusions on the same schedule. Stable use of locally approved ALS treatments was permitted.
Participants who completed the double-blind period could enter an optional 24-week open-label extension in which all participants received AP-101. To maintain the integrity of the double-blind period, the initial dose in the open-label extension remained blinded. Participants were followed for safety and pharmacokinetic assessments for up to 16 weeks after their final study dose.
The primary assessments evaluated adverse events, serious adverse events, immunogenicity, vital signs, clinical laboratory assessments, physical and neurological examinations, electrocardiograms, and changes in weight. Secondary assessments included serum pharmacokinetics, AP-101 concentrations in cerebrospinal fluid, and the neurofilament biomarkers phosphorylated neurofilament heavy chain (pNfH) and neurofilament light chain (NfL). Exploratory assessments included the ALS Functional Rating Scale-Revised, slow vital capacity, muscle strength, King's staging, survival and ventilation outcomes, quality of life, and cerebrospinal fluid total and misfolded SOD1.
The criteria were revised on the registry on Sep 30, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AP-101 is administered by intravenous infusion (IV).
Drug: AP-101
Placebo is administered by intravenous infusion (IV).
Drug: Placebo
Participants receive AP-101 by intravenous infusion (IV).
Participants receive placebo by intravenous infusion (IV).
Participants With Treatment-Emergent Adverse Events (TEAE) and Treatment-Emergent Serious Adverse Events (TESAE) During the Double-Blind Period
Treatment-emergent adverse events were adverse events that began or worsened after the first dose of randomized study treatment during the double-blind period. Treatment-emergent serious adverse events met the protocol-defined criteria for seriousness. Participants experiencing more than one event within a category were counted once in that category. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.
Time frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
Number of Participants With Abnormalities in Vital Signs, Clinical Laboratory Assessments, Physical and Neurological Examinations, and Electrocardiograms
Number of participants with at least one abnormality in vital signs, clinical laboratory assessments, physical examinations, neurological examinations, or electrocardiograms during the double-blind period. Participants could be included in more than one category; therefore, categories were not mutually exclusive. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.
Time frame: From the first dose through the 21-day follow-up after Week 24, approximately 27 weeks
Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind Period
Serum samples were assessed for anti-drug antibodies to AP-101. Participants were evaluable for treatment-emergent anti-drug antibodies if they had at least one non-missing baseline result and at least one non-missing post-baseline result. One participant was anti-drug-antibody positive at baseline and subsequently tested negative; baseline positivity was not classified as treatment-emergent. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts. ADA testing was not assessed in placebo participants.
Time frame: From baseline through the 21-day follow-up after Week 24, approximately 27 weeks
Model-Derived Elimination Half-Life of AP-101 in Serum
The individual elimination half-life of AP-101 was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. The model used pooled serum AP-101 concentration data from studies AP101-01 and AP101-02. This outcome summarizes participants from AP101-02 who were included in the final population pharmacokinetic model.
Time frame: From the first AP-101 dose through 16 weeks after the final AP-101 dose, up to approximately 64 weeks
Model-Derived Area Under the Serum AP-101 Concentration-Time Curve
Individual AP-101 exposure was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Area under the concentration-time curve during the dosing interval was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.
Time frame: AUC following the second active dose: Day 2 through Day 22; AUC at steady state: the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study
Model-Derived Maximum Serum AP-101 Concentration
Individual maximum serum AP-101 concentrations were estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Maximum concentration was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.
Time frame: Cmax following the second active dose: Day 2 through Day 22; Cmax at steady state: during the 21-day dosing interval following the participant's final active AP-101 dose, which occurred up to approximately Week 48 of the study.
AP-101 Concentration in Cerebrospinal Fluid During the Double-Blind Period
AP-101 concentrations were measured in cerebrospinal fluid to assess central nervous system exposure after repeated intravenous dosing. Samples were collected at Week 12 and Week 24 of the double-blind period and summarized by ALS cohort and visit among participants with quantifiable CSF AP-101 concentrations. Actual concentrations were reported rather than change from baseline because nearly all baseline concentrations were below the limit of quantitation.
Time frame: Week 12 and Week 24 of the double-blind period
Change From Baseline in Cerebrospinal Fluid Phosphorylated Neurofilament Heavy Chain (pNfH) During the Double-Blind Period
Phosphorylated neurofilament heavy chain (pNfH) concentrations were measured in cerebrospinal fluid at baseline, Week 12, and Week 24. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.
Time frame: Baseline to Week 24 of the double-blind period
Change From Baseline in Serum Neurofilament Light Chain During the Double-Blind Period and 21-Day Follow-up
Neurofilament light chain (NfL) concentrations were measured in serum at baseline, Week 12, Week 24, and the 21-day follow-up after completion of double-blind treatment. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.
Time frame: Baseline through the 21-day follow-up after Week 24, approximately 27 weeks
The study was conducted at 14 study centers; 13 centers enrolled participants. A total of 83 participants were screened and 73 were randomized and received study treatment.
| Milestone | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo |
|---|---|---|---|---|
| Started | 34 | 18 | 14 | 7 |
| Completed | 23 | 15 | 13 | 3 |
| Not completed | 11 | 3 | 1 | 4 |
| Withdrew: Withdrawal by subject | 7 | 0 | 1 | 0 |
| Withdrew: Adverse event | 2 | 1 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 1 |
| Withdrew: Enrollment in another clinical study | 0 | 0 | 0 | 1 |
| Withdrew: At ole week 3, svc was 41%, niv use was >6 hours/night, and orthopnea had developed. | 1 | 0 | 0 | 0 |
| Withdrew: Did not complete all protocol specified follow up assessments | 1 | 0 | 0 | 0 |
| Withdrew: Incorrect enrollment in the study | 0 | 1 | 0 | 0 |
| Milestone | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo |
|---|---|---|---|---|
| Started | 23 | 15 | 13 | 3 |
| Completed | 19 | 11 | 12 | 2 |
| Not completed | 4 | 4 | 1 | 1 |
| Withdrew: Withdrawal by subject | 3 | 2 | 1 | 0 |
| Withdrew: Adverse event | 1 | 2 | 0 | 1 |
Treatment-emergent adverse events were adverse events that began or worsened after the first dose of randomized study treatment during the double-blind period. Treatment-emergent serious adverse events met the protocol-defined criteria for seriousness. Participants experiencing more than one event within a category were counted once in that category. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.
| participants | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo |
|---|---|---|---|---|
| At Least One TEAE | 33 | 17 | 13 | 6 |
| At Least One TESAE | 6 | 4 | 0 | 3 |
Number of participants with at least one abnormality in vital signs, clinical laboratory assessments, physical examinations, neurological examinations, or electrocardiograms during the double-blind period. Participants could be included in more than one category; therefore, categories were not mutually exclusive. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts.
| participants | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo |
|---|---|---|---|---|
| Vital Sign Abnormality | 23 | 12 | 4 | 3 |
| Clinical Laboratory Assessment Abnormality | 3 | 3 | 1 | 0 |
| Physical Examination Abnormality | 34 | 18 | 14 | 7 |
| Neurological Examination Abnormality | 34 | 18 | 14 | 7 |
| Electrocardiogram Abnormality | 26 | 14 | 4 | 3 |
| Any of the Above Abnormalities | 34 | 18 | 14 | 7 |
Serum samples were assessed for anti-drug antibodies to AP-101. Participants were evaluable for treatment-emergent anti-drug antibodies if they had at least one non-missing baseline result and at least one non-missing post-baseline result. One participant was anti-drug-antibody positive at baseline and subsequently tested negative; baseline positivity was not classified as treatment-emergent. Results are presented separately for the sporadic ALS and SOD1-associated ALS cohorts. ADA testing was not assessed in placebo participants.
| participants | Sporadic ALS - AP-101 | SOD1-Associated ALS - AP-101 |
|---|---|---|
| Participants With Treatment-Emergent Anti-Drug Antibodies (ADAs) During the Double-Blind Period | 0 | 0 |
The individual elimination half-life of AP-101 was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. The model used pooled serum AP-101 concentration data from studies AP101-01 and AP101-02. This outcome summarizes participants from AP101-02 who were included in the final population pharmacokinetic model.
| hours | All Participants Receiving AP-101 |
|---|---|
| Model-Derived Elimination Half-Life of AP-101 in Serum | 515.77 ± 133.80 |
Individual AP-101 exposure was estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Area under the concentration-time curve during the dosing interval was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.
| µg·h/mL | All Participants Receiving AP-101 |
|---|---|
| AUC During the Dosing Interval Following the Second Active Dose (Day 2 through Day 22) | 125585.05 ± 35634.55 |
| AUC During the 21-day Dosing Interval at Steady State (approximately Week 48 of the study) | 203818.06 ± 69764.09 |
Individual maximum serum AP-101 concentrations were estimated using empirical Bayes estimates from the final two-compartment population pharmacokinetic model. Maximum concentration was estimated following the second active AP-101 dose and at steady state. This outcome summarizes AP101-02 participants included in the final population pharmacokinetic model.
| µg/mL | All Participants Receiving AP-101 |
|---|---|
| Maximum Serum Concentration (Cmax) Following the Second Active Dose (Day 2 through Day 22) | 930.84 ± 161.78 |
| Maximum Serum Concentration (Cmax) at Steady State (approximately Week 48 of the study) | 1058.09 ± 200.94 |
AP-101 concentrations were measured in cerebrospinal fluid to assess central nervous system exposure after repeated intravenous dosing. Samples were collected at Week 12 and Week 24 of the double-blind period and summarized by ALS cohort and visit among participants with quantifiable CSF AP-101 concentrations. Actual concentrations were reported rather than change from baseline because nearly all baseline concentrations were below the limit of quantitation.
| micrograms per milliliter | Participants With Quantifiable CSF AP-101 Concentrations |
|---|---|
| Sporadic ALS: Week 12 | 1.23 ± 0.76 |
| Sporadic ALS: Week 24 | 1.18 ± 0.70 |
| SOD1-ALS: Week 12 | 0.92 ± 0.45 |
| SOD1-ALS: Week 24 | 1.08 ± 0.43 |
Phosphorylated neurofilament heavy chain (pNfH) concentrations were measured in cerebrospinal fluid at baseline, Week 12, and Week 24. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.
| ng/mL | AP-101 | Placebo |
|---|---|---|
| Sporadic ALS: Week 12 Change From Baseline | -0.249 ± 0.5923 | 0.105 ± 0.4137 |
| Sporadic ALS: Week 24 Change From Baseline | 0.132 ± 1.3406 | 0.236 ± 0.5716 |
| SOD1-ALS: Week 12 Change From Baseline | -0.379 ± 0.9801 | -0.595 ± 1.1599 |
| SOD1-ALS: Week 24Change From Baseline | -0.115 ± 1.2342 | 0.360 ± 0.9057 |
Neurofilament light chain (NfL) concentrations were measured in serum at baseline, Week 12, Week 24, and the 21-day follow-up after completion of double-blind treatment. Results represent the mean change from baseline and are presented separately for the sporadic ALS and SOD1-ALS cohorts. Negative values indicate a decrease from baseline.
| pg/mL | AP-101 | Placebo |
|---|---|---|
| Sporadic ALS: Week 12 Change From Baseline | -3.07 ± 18.046 | -6.01 ± 33.720 |
| Sporadic ALS: Week 24 Change From Baseline | 18.00 ± 56.691 | -3.42 ± 41.658 |
| Sporadic ALS: 21-Day Follow-up Change From Baseline | -6.51 ± 15.193 | 1.44 ± 27.570 |
| SOD1-ALS: Week 12 Change From Baseline | -3.23 ± 9.780 | -3.36 ± 19.135 |
| SOD1-ALS: Week 24 Change From Baseline | -1.48 ± 9.110 | 15.35 ± 66.290 |
| SOD1-ALS: 21-Day Follow-up Change From Baseline | 3.30 ± 12.217 | -22.00 ± 18.385 |
Collected over From the first dose of randomized study treatment through 16 weeks after the participant's final study dose, up to approximately 64 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| AP-101 Exposure | 9/66 (13.6%) | 19/66 (28.8%) | 64/66 (97%) |
| Placebo Exposure | 1/25 (4%) | 7/25 (28%) | 23/25 (92%) |
| Event | AP-101 Exposure | Placebo Exposure |
|---|---|---|
| DysphagiaGastrointestinal disorders | 5/66 | 3/25 |
| PneumoniaInfections and infestations | 2/66 | 2/25 |
| Respiratory failureRespiratory, thoracic and mediastinal disorders | 3/66 | 1/25 |
| Pneumonia aspirationInfections and infestations | 3/66 | 1/25 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/66 | 1/25 |
| Pneumonia pneumococcalInfections and infestations | 0/66 | 1/25 |
| ConcussionInjury, poisoning and procedural complications | 0/66 | 1/25 |
| Respiratory distressRespiratory, thoracic and mediastinal disorders | 2/66 | 0/25 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/66 | 0/25 |
| HypoventilationRespiratory, thoracic and mediastinal disorders | 1/66 | 0/25 |
| Event | AP-101 Exposure | Placebo Exposure |
|---|---|---|
| FallInjury, poisoning and procedural complications | 25/66 | 11/25 |
| NasopharyngitisInfections and infestations | 23/66 | 5/25 |
| DiarrhoeaGastrointestinal disorders | 11/66 | 0/25 |
| HeadacheNervous system disorders | 11/66 | 3/25 |
| COVID-19Infections and infestations | 9/66 | 2/25 |
| RashSkin and subcutaneous tissue disorders | 8/66 | 3/25 |
| RhinitisInfections and infestations | 0/66 | 3/25 |
| ConstipationGastrointestinal disorders | 5/66 | 3/25 |
| ContusionInjury, poisoning and procedural complications | 4/66 | 3/25 |
| Weight decreasedInvestigations | 3/66 | 3/25 |
Safety Population: all randomized participants who received at least one dose of study treatment. Baseline characteristics are presented separately by ALS cohort and randomized treatment assignment.
| Age, Continuous(years) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Mean | 57.8 ± 9.26 | 59.7 ± 10.82 | 45.6 ± 13.34 | 48.6 ± 8.66 | 55.05 ± 11.65 |
| Sex: Female, Male(Participants) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Female | 9 | 4 | 5 | 3 | 21 |
| Male | 25 | 14 | 9 | 4 | 52 |
| Ethnicity (NIH/OMB)(Participants) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 0 | 0 | 2 |
| Not Hispanic or Latino | 32 | 18 | 14 | 7 | 71 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 4 | 1 | 1 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 26 | 14 | 13 | 6 | 59 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Body Mass Index(kg/m²) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Mean | 26.132 ± 4.0288 | 25.111 ± 3.0386 | 27.829 ± 5.8555 | 26.600 ± 5.7703 | 26.251 ± 4.406 |
| Months Since ALS Diagnosis(months) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Mean | 6.390 ± 5.2404 | 5.206 ± 3.3429 | 3.826 ± 3.5048 | 4.281 ± 2.5828 | 5.404 ± 4.367 |
| Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score(point based scores on a scale) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Mean | 39.3 ± 3.77 | 38.7 ± 5.31 | 40.9 ± 5.16 | 37.7 ± 4.46 | 39.31 ± 4.52 |
| Riluzole Use(Participants) | Sporadic ALS - AP-101 | Sporadic ALS - Placebo | SOD1-Associated ALS - AP-101 | SOD1-Associated ALS - Placebo | Total |
|---|---|---|---|---|---|
| Count of participants | 34 | 18 | 12 | 7 | 71 |
5 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2021 to primary completion in Aug 2025, 47 months.
Results were first posted in Sep 2026, 1 year 1 month after primary completion.
Of 36 industry-sponsored phase 2 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 35. This study's 47 months is above that.
Counting every sponsor, half of 73 studies reached it within 24 months; a quarter within 16 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Episalvan
Amyotrophic Lateral Sclerosis →
AL-S Pharma